Summary
Ocular Therapeutix Inc Ocular, formerly ITherapeutix Inc is a biopharmaceutical company that discovers, develops, manufactures and commercializes therapies for diseases using hydrogel platform technology. The company's products include DEXTENZA, sustained release travoprost and posterior segment injections. Its hydrogel technology uses polyethylene glycol to create ophthalmic sustained drug delivery systems. Ocular's hydrogel provides containment, localization and protection from inflammatory response, and a material for sustained delivery of drugs to the eye. The company also provides ReSure Sealant, a ocular sealant proven in clinical trial to be safe in sealing clear corneal incisions following cataract surgery. Its products are used for the treatment of glaucoma and ocular hypertension, postoperative inflammation, allergic conjunctivitis, dry eye and retinal diseases. Ocular is headquartered in Bedford, Massachusetts, the US.
This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Ocular Therapeutix Inc
The report provides pipeline analysis on all pipeline products of the company by equipment type, by indication, by development stage, and by trial status
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indications, applications and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials wherever applicable with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research Development strategies
Develop marketentry and market expansion strategies
Exploit inlicensing and outlicensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next highvalue products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company